Review
Immunology
Ding-Yu Rao, De-Fa Huang, Mao-Yan Si, Hua Lu, Zhi-Xian Tang, Zu-Xiong Zhang
Summary: As an important mediator of information transfer between cells, exosomes play a unique role in regulating tumor growth, supporting vascular proliferation, tumor invasion, and metastasis. Exosomes can be used as a potential tool for non-invasive liquid biopsy due to their presence in various body fluids. This study reviews the role of exosomes in liquid biopsy, tumor microenvironment formation, and epithelial-mesenchymal transition in non-small cell lung cancer (NSCLC). It also discusses the occurrence of EGFR+ exosomes and the role of exosomes and their contents in non-invasive detection and potential therapeutic targets in EGFR-mutated lung cancer.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Isa Mambetsariev, Leonidas Arvanitis, Jeremy Fricke, Rebecca Pharaon, Angel R. Baroz, Michelle Afkhami, Marianna Koczywas, Erminia Massarelli, Ravi Salgia
Summary: EGFR-mutated lung adenocarcinoma patients can transform into SCLC after receiving TKI therapy. This study evaluated 9 patients who underwent such transformation and found that they had unique clinical, molecular, and histological characteristics at different time points. The findings are important for understanding the molecular heterogeneity and clinical outcomes of this EGFR TKI resistance subtype.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Meina Wang, Roy S. Herbst, Chris Boshoff
Summary: Over the past two decades, molecular targeted therapies and immunotherapies have significantly improved outcomes for non-small-cell lung cancer (NSCLC), but the majority of advanced NSCLCs eventually become resistant. The future challenge lies in the application of predictive biomarkers for patient stratification in order to better manage NSCLC.
Review
Surgery
Chai Hong Rim, Won Kyung Cho, Sunmin Park, Won Sup Yoon, Dae Sik Yang
Summary: This meta-analysis confirms the oncologic role of local ablative treatment (LAT) in treating oligometastatic nonsmall cell lung cancer, with synchronous and oligopersistent disease showing more benefit than oligoprogression/recurrence disease.
INTERNATIONAL JOURNAL OF SURGERY
(2023)
Review
Oncology
Lin Zhang, Weihao Lin, Fengwei Tan, Ning Li, Qi Xue, Shugeng Gao, Yibo Gao, Jie He
Summary: This study provides an overview of the clinical trials on Sintilimab for non-small cell lung cancer (NSCLC) conducted in China, showing its effectiveness and tolerability, but further research is needed.
BIOMARKER RESEARCH
(2022)
Letter
Medicine, General & Internal
Hollis Viray, Deepa Rangachari, Daniel B. Costa
Summary: The study reported initial data of trastuzumab deruxtecan in the treatment of lung cancers with ERBB2 mutations, including patients who had previously received ineffective ERBB2 tyrosine kinase inhibitors.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Immunology
Ting Zhou, Li-Ying Zhang, Jian-Zheng He, Zhi-Ming Miao, Yang-Yang Li, Yi-Ming Zhang, Zhi-Wei Liu, Shang-Zu Zhang, Yan Chen, Gu-Cheng Zhou, Yong-Qi Liu
Summary: Radiotherapy is the main treatment for non-small cell lung cancer (NSCLC), but radioresistance and toxicity are major obstacles. Factors such as oncogenic mutation, cancer stem cells, tumor hypoxia, DNA damage repair, epithelial-mesenchymal transition, and tumor microenvironment contribute to radioresistance. Combining chemotherapy drugs, targeted drugs, and immune checkpoint inhibitors with radiotherapy improves efficacy. This article reviews the potential mechanisms of radioresistance in NSCLC, discusses current drug research to overcome resistance, and highlights the advantages of Traditional Chinese Medicine in improving efficacy and reducing toxicity.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Si-Yang Maggie Liu, Mei-Mei Zheng, Yi Pan, Si-Yang Liu, Yangqiu Li, Yi-Long Wu
Summary: Research on biomarker-driven therapy and immunotherapy in non-small cell lung cancer (NSCLC) is rapidly advancing, with improving clinical trials and personalized treatment paradigms. This review summarizes promising agents that have changed the treatment approach for NSCLC patients, including targeted therapy and checkpoint inhibitors. Proposed treatment algorithms and ongoing clinical trials aim to address remaining clinical issues and impact future clinical practice.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Review
Oncology
Jing Han, Yang Liu, Sen Yang, Xuan Wu, Hongle Li, Qiming Wang
Summary: BRAF and KRAS mutations play a significant role in NSCLC by activating the RAS/RAF/MEK/ERK signaling pathway. Current approved therapies include BRAF and MEK inhibitors, while combination with other drugs may enhance therapeutic effects. Further research is needed to explore optimal drug combinations for treating lung cancer patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Oncology
Maria Gabriela O. Fernandes, Natalia Cruz-Martins, Jose Carlos Machado, Jose Luis Costa, Venceslau Hespanhol
Summary: Liquid biopsy, specifically plasma ctDNA analysis, has revolutionized cancer patient management by detecting genomic alterations and resistance mechanisms, particularly in lung cancer patients. While offering a comprehensive view of tumor diversity, its non-invasive nature overcomes the challenges of obtaining tissue samples. Further clarification is needed regarding the use of LB in supporting diagnostic and therapeutic decisions.
CANCER CELL INTERNATIONAL
(2021)
Article
Medicine, General & Internal
Valerio Nardone, Alfonso Reginelli, Giuseppina De Marco, Giovanni Natale, Vittorio Patane, Marco De Chiara, Mauro Buono, Gaetano Maria Russo, Riccardo Monti, Giovanni Balestrucci, Maria Salvarezza, Gaetano Di Guida, Emma D'Ippolito, Angelo Sangiovanni, Roberta Grassi, Ida D'Onofrio, Maria Paola Belfiore, Giovanni Cimmino, Carminia Maria Della Corte, Giovanni Vicidomini, Alfonso Fiorelli, Antonio Gambardella, Floriana Morgillo, Salvatore Cappabianca
Summary: Treatment-induced cardiac toxicity is a significant issue in NSCLC patients, with no available biomarkers in clinical practice. The Agatston score (or CAD score) is a novel and easy-to-calculate marker for quantitative analysis of calcium plaque in the coronary on CT. Our study aimed to correlate cardiac biomarkers with overall survival in NSCLC patients.
Review
Oncology
Krisztian Sueveg, Ludwig Plasswilm, Thomas Iseli, Pawel Leskow, Galina Farina Fischer, Paul Martin Putora
Summary: The use of postoperative radiotherapy (PORT) in completely resected non-small cell lung cancer (NSCLC) with ipsilateral mediastinal lymph node involvement (pN2) is controversial. Guidelines do not recommend the routine use of PORT due to conflicting results. Future research should focus on identifying subgroups of patients who might benefit from PORT.
Article
Oncology
Caleb J. Euhus, Taylor R. Ripley, Cristian G. Medina
Summary: This article clarifies the concept and definition of oligometastatic non-small cell lung cancer (NSCLC) and reviews the current results in the use of surgery for its management. Oligometastatic NSCLC refers to a subgroup of patients with limited metastases, who seem to have a slower disease progression compared to those with widespread metastases. A missed opportunity to improve survival may occur if palliative systemic therapy is prioritized over local aggressive treatment for these select patients.
Article
Pharmacology & Pharmacy
Rebeca Carrion-Marchante, Celia Pinto-Diez, Jose Ignacio Klett-Mingo, Esther Palacios, Miriam Barragan-Usero, M. Isabel Perez-Morgado, Manuel Pascual-Mellado, Sonia Alcala, Laura Ruiz-Canas, Bruno Sainz Jr, Victor M. Gonzalez, M. Elena Martin
Summary: Lung cancer is a major cause of cancer-related death worldwide. A previously identified aptamer, apMNKQ2, showed promising results as an antitumor drug in breast cancer. This study investigates the antitumor potential of apMNKQ2 in non-small cell lung cancer where MNK1 plays a significant role.
Review
Oncology
Yuqiu Hao, Hongna Dong, Wei Li, Xuejiao Lv, Bingqing Shi, Peng Gao
Summary: This study explores the role of IL-35 in the pathogenesis of non-small cell lung cancer (NSCLC) and provides new insights into its therapeutic potential.
FRONTIERS IN ONCOLOGY
(2022)
